Arcellx, Inc. ACLX
We take great care to ensure that the data presented and summarized in this overview for Arcellx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACLX
View all-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$398 Million14.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$338 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$321 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$301 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$260 Million4.37% of portfolio
-
Vestal Point Capital, LP New York, NY2.75MShares$235 Million9.53% of portfolio
-
Perceptive Advisors LLC New York, NY2.48MShares$212 Million7.17% of portfolio
-
Sr One Capital Management, LP2.35MShares$201 Million55.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.94MShares$166 Million0.08% of portfolio
-
State Street Corp Boston, MA1.59MShares$136 Million0.0% of portfolio
Latest Institutional Activity in ACLX
Top Purchases
Top Sells
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Transactions at ACLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,364
-38.79%
|
$488,124
$91.04 P/Share
|
|
Oct 06
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,064
-7.14%
|
$91,504
$86.22 P/Share
|
|
Oct 03
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,882
-24.69%
|
$419,852
$86.0 P/Share
|
|
Sep 30
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
21,034
-60.78%
|
$1,703,754
$81.4 P/Share
|
|
Sep 29
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
73
-0.34%
|
$5,840
$80.16 P/Share
|
|
Sep 26
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,396
-36.32%
|
$991,680
$80.12 P/Share
|
|
Sep 19
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
300
-0.87%
|
$24,000
$80.0 P/Share
|
|
Sep 18
2025
|
Christopher Heery CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,343
-8.85%
|
$267,440
$80.01 P/Share
|
|
Aug 28
2025
|
Rami Elghandour |
SELL
Payment of exercise price or tax liability
|
Direct |
546,938
-46.95%
|
$38,285,660
$70.25 P/Share
|
|
Aug 12
2025
|
Ali Behbahani |
BUY
Other acquisition or disposition
|
Indirect |
2,621
+49.2%
|
-
|
|
Aug 12
2025
|
Ali Behbahani |
BUY
Other acquisition or disposition
|
Direct |
1,586
+45.17%
|
-
|
|
Jun 10
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$100,500
$67.36 P/Share
|
|
Jun 10
2025
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
May 27
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,235
-20.88%
|
$770,805
$64.0 P/Share
|
|
May 23
2025
|
Michelle Gilson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,429
+41.2%
|
-
|
|
May 20
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$87,000
$58.43 P/Share
|
|
May 20
2025
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Apr 29
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$96,000
$64.2 P/Share
|
|
Apr 29
2025
|
Kavita Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$9,000
$6.66 P/Share
|
|
Apr 08
2025
|
Kavita Patel |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$85,500
$57.5 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 4.21K shares |
|---|---|
| Exercise of conversion of derivative security | 582K shares |
| Grant, award, or other acquisition | 1.02M shares |
| Open market or private sale | 307K shares |
|---|---|
| Payment of exercise price or tax liability | 547K shares |